Svetlana Ganetsky, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 197 Edwards Dr, Churchville, PA 18966 Phone: 215-355-4870 Fax: 215-355-4870 |
Cheryl Bryant Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 53 Acorn Dr, Churchville, PA 18966 Phone: 215-942-7750 |
Dr. Kathryn Ann Barry, DPT Physical Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 8 Charlotte Dr, Churchville, PA 18966 Phone: 215-322-1447 |
Dvorah Keren Lichtenstein Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 176 Stratford Dr, Churchville, PA 18966 Phone: 215-357-1662 |
Michelle Dee Mccallister, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 79 New Rd, Churchville, PA 18966 Phone: 267-240-1680 |
News Archive
An interdisciplinary team of scientists from KU Leuven, the University of Bremen, the Leibniz Institute of Materials Engineering, and the University of Ioannina has succeeded in killing tumour cells in mice using nano-sized copper compounds together with immunotherapy. After the therapy, the cancer did not return.
Scientists have found evidence that the reduced effectiveness of breast screening in women in their 40s is mainly due to their tumours being harder to detect, rather than because they grow faster.Previous research has suggested that breast screening is less effective in women in their 40s than in older women.Two reasons have been identified for this - firstly, that younger women tend to have denser breast tissue which makes it harder to detect tumours on a mammogram; and secondly, because younger women's tumours tend to grow more quickly.
Women who experience early menopause appear to have more than twice the risk of having a heart attack, stroke or other cardiovascular disease event later in life than do women who do not go through early menopause, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.
Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg AriceptĀ® (donepezil HCl extended release) tablets for the treatment of moderate to severe Alzheimer's disease (AD).
› Verified 8 days ago